Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
UBS
Harvard Business School
Baxter
Medtronic
McKesson
Julphar
Cerilliant
US Army

Generated: November 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207958

« Back to Dashboard

NDA 207958 describes SPRITAM, which is a drug marketed by Aprecia Pharms and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the SPRITAM profile page.

The generic ingredient in SPRITAM is levetiracetam. There are thirty-five drug master file entries for this compound. Ninety-seven suppliers are listed for this compound. Additional details are available on the levetiracetam profile page.
Summary for 207958
Tradename:SPRITAM
Applicant:Aprecia Pharms
Ingredient:levetiracetam
Patents:4
Formulation / Manufacturing:see details
Pharmacology for NDA: 207958
Suppliers and Packaging for NDA: 207958
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958 NDA Aprecia Pharmaceuticals, LLC 43485-101 43485-101-60 60 BLISTER PACK in 1 CARTON (43485-101-60) > 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (43485-101-01)
SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958 NDA Aprecia Pharmaceuticals, LLC 43485-102 43485-102-60 60 BLISTER PACK in 1 CARTON (43485-102-60) > 1 TABLET, FOR SUSPENSION in 1 BLISTER PACK (43485-102-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, FOR SUSPENSION;ORALStrength250MG
Approval Date:Jul 31, 2015TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Feb 20, 2018Product Flag?YSubstance Flag?Delist Request?
Patent:➤ Try a Free TrialPatent Expiration:Mar 14, 2034Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHOD OF ADMINISTERING LEVETIRACETAM
Patent:➤ Try a Free TrialPatent Expiration:Feb 20, 2018Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 207958

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-002 Jul 31, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-003 Jul 31, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-004 Jul 31, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-002 Jul 31, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-003 Jul 31, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-001 Jul 31, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-001 Jul 31, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
AstraZeneca
Julphar
Teva
Johnson and Johnson
Queensland Health
Express Scripts
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.